https://www.selleckchem.com/pr....oducts/harringtonine
We assessed whether and to what extent established cardiovascular disease (CVD) risk factors moderate (enhance/reduce) the effect of hyperglycemia on CVD outcomes in the long-term follow-up of the Diabetes Control and Complications Trial type 1 diabetes (T1D) cohort (N=1441). Moderation of the effect of glycemia on subsequent risk of major adverse cardiovascular events (MACE fatal or non-fatal myocardial infarction or stroke) and any-CVD (MACE plus confirmed angina, silent MI, revascularization, or congestive heart failure) was as
Like
Comment
Share
